Prosecution Insights
Last updated: November 20, 2026
Application No. 19/199,269

Catheter Insertion-Tray Systems and Methods Thereof

Non-Final OA §102§103§DOUBLEPATENT
Filed
May 05, 2025
Priority
Mar 31, 2017 — provisional 62/479,687 +3 more
Examiner
LEVY, BRANDON WILLIAM
Art Unit
3781
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
C.R. Bard Inc.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
1y 6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
124 granted / 197 resolved
-7.1% vs TC avg
Strong +46% interview lift
Without
With
+46.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
28 currently pending
Career history
235
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
56.8%
+16.8% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 197 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-5, 7-8, and 10-16 are rejected under 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) as being anticipated by Icenogle (WO 2015057999). Regarding claim 1, Icenogle discloses a catheterization tray (abstract), comprising: a sterile side configured to enable a user to carry out sterile steps of a catheterization procedure in a sterile field (paragraph 00146, “multiple compartments for housing and/or securing… other sterile and/or non-sterile catheterization elements”, also see fig. 31A, first side on the right of interior wall 212 capable of serving as a sterile side of the tray”); a set of sterile items positioned in the sterile side (fig. 31A, sterile items including catheter 191 and urine collection bag 192, which according to [0006] of the instant specification, drainage tubing and drainage bag are considered sterile items); a non-sterile side configured to enable a user to carry out non-sterile steps of the catheterization procedure outside of the sterile field (paragraph 00146, “multiple compartments for housing and/or securing… other sterile and/or non-sterile catheterization elements”, also see fig. 31A, second side to the left interior wall 212 and is capable of serving for performing non-sterile steps of the catheterization procedure outside the sterile field); a set of non-sterile items positioned in the non-sterile side (fig. 31A, one or more swabs 150 cleaning solution packet 160); and a partition (212) extending between the sterile side and the non-sterile side from a first side wall of the catheterization tray to a second side wall of the catheterization tray (fig. 31A, separator wall 212 separating compartment in first and second sides as defined, paragraph 0081) to maintain sterility of the sterile side (fig. 31A, separator wall 212 keeping sterile and non-sterile components separate maintains sterility of the first side). Regarding claim 2, Icenogle discloses wherein the set of sterile items are ordered in accordance with a sterile work path (fig. 31A, sterile items to be used and ordered in a sterile work path). Regarding claim 3, Icenogle discloses wherein the set of non-sterile items are ordered in accordance with a non-sterile work path (fig. 31A, non-sterile items to be used and ordered in a non-sterile work path). Regarding claim 4, Icenogle discloses further comprising a sterile wrap (56) and a belly band (46) configured to hold the sterile wrap around the catheterization tray (fig. 20, belly band 46 and sterile wrap 56, see paragraph 0013, “belly band may be positioned outside the sterile wrap”). Regarding claim 5, Icenogle discloses the device further comprising a perineal care kit (74) positioned outside of the sterile wrap (paragraph 0014, “adding a peri-care kit to the catheterization tray outside the belly band and sterile wrap”) along with a package of hand sanitizer (paragraph 0014, “peri-care kit to the catheterization tray outside the belly band and sterile wrap, the peri-care kit including… hand sanitizer”, see fig. 19, hand sanitizer 76). Regarding claim 7, Icenogle discloses the device further comprising at least a first pair of gloves positioned inside of the sterile wrap (fig. 23, “package 58 of sterile gloves”, see paragraph 0075, “Catheterization package may include… gloves”). Regarding claim 8, Icenogle discloses wherein the set of sterile items include a drainage system and a catheter (fig. 31A, sterile items includes catheter 191 and urine collection bag 192). Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Icenogle in view of Hakky (US 20050101941) Regarding claim 10, Icenogle discloses wherein the set of non-sterile items include a waterproof underpad (86) configured for placement under a patient (fig. 24, folded pad/drape 86, see paragraph 00131 on the second side) and a fenestrated drape configured for placement over the patient (fig. 24, folded pad/drape 86, see paragraph 00131, “(1) waterproof underpad, and (2) a separate fenestrated drape”, also see paragraph 00199 and fig. 34, “the side cutouts 272 may facilitate placement of the fenestrated drape 270 about the legs of the patient”). Regarding claim 11, wherein the set of non-sterile items further include a skin-preparation kit including a package of an antiseptic and one or more swabs configured for preparing the patient for inserting a urinary catheter. Regarding claim 12, Icenogle discloses the device further comprising instructions for the catheterization procedure imprinted directly on a surface of the catheterization tray (see Icenogle’s abstract, “tray is intuitively arranged and includes instructions printed thereon”), the instructions revealed in accordance with the sterile steps and the non-sterile steps of the catheterization procedure as the set of sterile items and the set of non-sterile items are removed from the catheterization tray (see Icenogle’s paragraph 0011, “the instructions/procedural indicators, and implements are arranged in an arrangement such that the medical procedure proceeds intuitively from step to step based on the arrangement”, also see Icenogle’s fig. 5, sterile steps of Foley Care and Maintenance near fillets 18, and steps that would belong on the non-sterile side including retracting genitalia and prepping patient with swabs above interior wall 12). Regarding claim 13, Icenogle discloses a method of using a catheterization package (abstract), comprising: unwrapping the catheterization package to reveal a catheterization tray (paragraph 00145, “The tray and components may be sterilized”, paragraph 00158, “following steps: (1) open CSR sterile wrap 130”), the catheterization tray comprising: a sterile side configured to enable a user to carry out sterile steps of a catheterization procedure in a sterile field (paragraph 00146, “multiple compartments for housing and/or securing… other sterile and/or non-sterile catheterization elements”, also see fig. 31A, first side on the right of interior wall 212 capable of serving as a sterile side of the tray); a non-sterile side configured to enable a user to carry out non-sterile steps of the catheterization procedure outside of the sterile field (paragraph 00146, “multiple compartments for housing and/or securing… other sterile and/or non-sterile catheterization elements”, also see fig. 31A, second side to the left interior wall 212 and is capable of serving for performing non-sterile steps of the catheterization procedure outside the sterile field); and a partition (212) extending between the sterile side and the non-sterile side from a first side wall of the catheterization tray to a second side wall of the catheterization tray (fig. 31A, separator wall 212 separating compartment in first and second sides as defined, paragraph 0081) to maintain sterility of the sterile side (fig. 31A, separator wall 212 keeping sterile and non-sterile components separate maintains sterility of the first side). removing an underpad and a fenestrated drape from the non-sterile side of the catheterization tray (paragraph 00158, “following steps… (3) place underpad; (4) place fenestrated drape”, thereby removing the underpad and fenestrated drape from the packaging, see fig. 24, folded pad/drape 86); and removing a drainage system including a urinary catheter, drainage tubing, and a drainage bag from the sterile side of the catheterization tray (fig. 29, tubing 95 connected to a catheter and to urine collection bag 96, also see paragraph 00139, “immediately after the catheter has been properly placed in the patient… urine collection bag 96 may be unfolded and hung below the patient to collect urine as it rains from the patient”). Regarding claim 14, Icenogle discloses the method of using the catheterization package further comprising: removing a perineal care kit (74) and a package of hand sanitizer (76) from outside a sterile wrap of the catheterization package (fig. 18, peri-care kit 74 and hand sanitizer 76, paragraph 0013, “package may also include a peri-care kit located outside of the sterile wrap”, paragraph 00121, “peri-care kit may include hand sanitizer 76”), and cleaning a peri-urethral area of the patient with the perineal care kit 74 (paragraph 0013, “using the peri-care kit to cleanse a portion of the patient’s perineum prior to unwrapping the sterile wrap”). Regarding claim 15, Icenogle discloses the method further comprising: placing the underpad under a patient (see Icenogle, paragraph 00131, “The underpad may have a waterproof side and a liquid absorbent side. If so, the absorbent side is placed up under the patient”); and and placing the fenestrated drape (86) over the patient (paragraph 00131, “after placing the underpad, the health care provided places the fenestrated drape on the patient”) while maintaining the sterile field (paragraph 00146, “multiple compartments for housing and/or securing a ureteral catheter assembly… as well as other sterile and/or non-sterile catheterization elements… sterile catheterization elements may be housed… in a manner that the sterile elements remain uncontaminated by non-sterile catheterization elements”, thereby maintaining a sterile field). Regarding claim 16, Icenogle discloses the method further comprising: preparing a patient and the urinary catheter for catheterization (see Icenogle, paragraph 00194, “prepare patient with swabs”); and catheterizing the patient while maintaining the sterile field (paragraph 00146, “multiple compartments for housing and/or securing a ureteral catheter assembly… as well as other sterile and/or non-sterile catheterization elements… sterile catheterization elements may be housed… in a manner that the sterile elements remain uncontaminated by non-sterile catheterization elements”, thereby maintaining the sterile field). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim 6 is rejected under 35 U.S.C. 103 as being unpatentable over Icenogle in view of Macinnes (US 20110233079) Regarding claim 6, Icenogle does not teach the device further comprising at least a first pair of gloves positioned outside of the sterile wrap. However, Macinnes teaches a catheterization kit (abstract) wherein a pair of gloves 2402 is located outside the sterile wrap (paragraph 0116, “The sanitizer 2401 and gloves 2402 are shown placed atop the first portion 2301, but may be alternatively placed atop, and therefore outside of the sterile field…”). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the at least first pair of gloves of the two or more pairs of gloves is located outside the sterile wrap, as taught by Macinnes, for the purpose of allowing the practitioner to maintain the sterile field before touching any part of the packaging (see Macinnes, paragraph 0015, “the health care services provider may- before ever touching the catheter assembly or tray contents- apply the liquid hand sanitizer 2401 to their hands and dawn rubber gloves”), thereby eliminating the need for the practitioner to leave the sterile field to obtain gloves or wash their hands (see Macinnes, paragraph 0015, “The inclusion of these accessories in the packaging eliminates the need for the health care services provider to leave the sterile field to wash their hands, obtain gloves, and so forth”). Regarding claim 9, Icenogle discloses wherein the package includes a syringe of sterile water (paragraph 0075, “a syringe of sterile liquid (e.g., a 10cc syringe of sterile water”, see fig. 25, syringe 88) a container containing lubricant (paragraph 0075, “a packet or container of lubricant”, see fig. 25, container 89), and a sterile sample container (paragraph 0075, “sample container”, see fig. 25, sample container 54). Icenogle is silent to wherein the package includes a syringe of sterile saline, wherein the package comprises a sterile sample container, and fails to teach wherein the set of sterile items further include the syringe of sterile saline, a container containing lubricant, and a sterile sample container However, it would have been obvious to one of ordinary skill in the art before the effective filing date of claimed the invention to modify the sterile side such that the set of sterile items further include the syringe of sterile fluid, the container containing lubricant, and the sample container, as these would be the components that the practitioner would want to keep sterile to prevent potential infections to the patient and to prevent contamination to the sampling container that would ruin the sample, and since it has been held that choosing from a finite number of identified, predictable solutions (i.e., arrangements of the components of the catheterization tray that remain in a logical order) with a reasonable expectation of success is considered to be of ordinary skill in the art. (MPEP §2143(E) , “Obvious to try- choosing from a finite number of identified, predictable solutions with a reasonable expectation of success.) (MPEP §2143(E), “Obvious to try- choosing from a finite number of identified, predictable solutions with a reasonable expectation of success.). In this instance, relocating the syringe of the sterile fluid and the container containing lubricant in a way that would still lead to a logical order of operations for the practitioner and also be within the first side of the tray configured to be a sterile side of the tray, as the intuitive design of the tray appears to more so come from the order in which items are revealed (paragraph 00111, “For example, a first item may be revealed in the package, then once the first item is used, a second item that was underneath the first item is revealed, the second item being next logical item for use in the catheterization procedure”). Icenogle is silent to wherein the package includes a syringe of sterile saline, wherein the package comprises a sterile sample container However, Hakky teaches an indwelling urinary catheter (abstract) wherein the balloon 30 is filled with either sterile water or saline, treating them as equivalents in the art (paragraph 0038, “sterile water or saline, is needed to inflate the balloon 30”). NOTE: While Hakky doesn’t specify if the saline is sterile, Icenogle already discloses that the fluid is sterile. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the container of sterile fluid disclosed in Icenogle to substitute the sterile liquid with sterile saline, as taught and suggested by Hakky, for the purpose of providing a suitably sterile fluid to enter the balloon and prevent contamination, and because sterile water and sterile saline were art-recognized equivalents before the effective filing date of the invention, it would have been obvious to substitute the sterile water disclosed in Icenogle with sterile saline. Icenogle is silent to wherein the sample container is sterile. However, because the purpose of a sample container is to test the urine sample, one of ordinary skill in the art would appreciate the desire to keep the sample container otherwise sterile in order for no other materials such as external pathogens affect readings done on the urine sample. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 9-11, and 15-18 of U.S. Patent No. US 11896778. Although the claims at issue are not identical, they are not patentably distinct from each other because instant claim 1 contains substantially all of the limitations of patented claim 1, with the notable difference of not having as many technical features as claim 1. As such, patented claim 1 appears to be a more specific species of instant claim 1. A similar analysis to instant claim 13 can be made with respect to patented claim 15 Regarding claim 2, the patented application discloses wherein the set of sterile items are ordered in accordance with a sterile work path (claim 1). Regarding claim 3, the patented application discloses wherein the set of non-sterile items are ordered in accordance with a non-sterile work path (claim 1). Regarding claim 4, the patented application discloses the device further comprising a sterile wrap and a belly band configured to hold the sterile wrap around the catheterization tray (claim 2). Regarding claim 5, the patented application discloses the device further comprising a perineal care kit positioned outside of the sterile wrap along with a package of hand sanitizer (claims 1-2). Regarding claim 6, the patented application discloses the device further comprising at least a first pair of gloves positioned outside of the sterile wrap (claim 3). Regarding claim 7, the patented application discloses the device further comprising at least a first pair of gloves positioned inside of the sterile wrap (claim 4). Regarding claim 8, the patented application discloses wherein the set of sterile items include a drainage system and a catheter (claim 1). Regarding claim 9, the patented application discloses wherein the set of sterile items further include a syringe of sterile saline, a container containing lubricant, and a sterile sample container (claim 5), but is silent to wherein the sample container is sterile. However, because the purpose of a sample container is to test the urine sample, one of ordinary skill in the art would appreciate the desire to keep the sample container otherwise sterile in order for no other materials such as external pathogens affect readings done on the urine sample. Regarding claim 10, the patented application discloses wherein the set of non-sterile items include a waterproof underpad configured for placement under a patient and a fenestrated drape configured for placement over the patient (claim 9). Regarding claim 11, the patented application discloses wherein the set of non-sterile items further include a skin-preparation kit including a package of an antiseptic and one or more swabs configured for preparing the patient for inserting a urinary catheter (claim 10). Regarding claim 12, the patented application discloses the device further comprising instructions for the catheterization procedure imprinted directly on a surface of the catheterization tray, the instructions revealed in accordance with the sterile steps and the non-sterile steps of the catheterization procedure as the set of sterile items and the set of non-sterile items are removed from the catheterization tray (claim 11). Regarding claim 14, the patented application discloses the method further comprising: removing a perineal care kit and a package of hand sanitizer from outside a sterile wrap of the catheterization package; and cleaning a peri-urethral area of a patient with the perineal care kit (claim 16). Regarding claim 15, the patented application discloses the method further comprising: placing the underpad under a patient; and placing the fenestrated drape over the patient while maintaining the sterile field (claim 17). Regarding claim 16, the patented application discloses the method further comprising: preparing a patient and the urinary catheter for catheterization; and catheterizing the patient while maintaining the sterile field (claim 18). Claims 1-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 and 10-13 of U.S. Patent No. US 12290645. Although the claims at issue are not identical, they are not patentably distinct from each other because instant claim 1 contains substantially all of the limitations of patented claim 1, with the notable difference of not having as many technical features as claim 1. As such, patented claim 1 appears to be a more specific species of instant claim 1. A similar analysis to instant claim 13 can be made with respect to patented claim 10 Regarding claim 2, the patented application discloses wherein the set of sterile items are ordered in accordance with a sterile work path (claim 1). Regarding claim 3, the patented application discloses wherein the set of non-sterile items are ordered in accordance with a non-sterile work path (claim 1). Regarding claim 4, the patented application discloses the device further comprising a sterile wrap and a belly band configured to hold the sterile wrap around the catheterization tray (claim 2). Regarding claim 5, the patented application discloses the device further comprising a perineal care kit positioned outside of the sterile wrap along with a package of hand sanitizer (claim 2). Regarding claim 6, the patented application discloses the device further comprising at least a first pair of gloves positioned outside of the sterile wrap (claim 3). Regarding claim 7, the patented application discloses the device further comprising at least a first pair of gloves positioned inside of the sterile wrap (claim 4). Regarding claim 8, the patented application discloses wherein the set of sterile items include a drainage system and a catheter (claim 5). Regarding claim 9, the patented application discloses wherein the set of sterile items further include a syringe of sterile saline, a container containing lubricant, and a sterile sample container (claim 6). Regarding claim 10, the patented application discloses wherein the set of non-sterile items include a waterproof underpad configured for placement under a patient and a fenestrated drape configured for placement over the patient (claim 7). Regarding claim 11, the patented application discloses wherein the set of non-sterile items further include a skin-preparation kit including a package of an antiseptic and one or more swabs configured for preparing the patient for inserting a urinary catheter (claim 8). Regarding claim 12, the patented application discloses the device further comprising instructions for the catheterization procedure imprinted directly on a surface of the catheterization tray, the instructions revealed in accordance with the sterile steps and the non-sterile steps of the catheterization procedure as the set of sterile items and the set of non-sterile items are removed from the catheterization tray (claim 9). Regarding claim 14, the patented application discloses the method further comprising: removing a perineal care kit and a package of hand sanitizer from outside a sterile wrap of the catheterization package; and cleaning a peri-urethral area of a patient with the perineal care kit (claim 11). Regarding claim 15, the patented application discloses the method further comprising: placing the underpad under a patient; and placing the fenestrated drape over the patient while maintaining the sterile field (claim 12). Regarding claim 16, the patented application discloses the method further comprising: preparing a patient and the urinary catheter for catheterization; and catheterizing the patient while maintaining the sterile field (claim 13). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRANDON W LEVY whose telephone number is (571)272-7582. The examiner can normally be reached M-F 7:30AM- 4:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Rebecca Eisenberg can be reached at 5712705879. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Brandon W. Levy/Examiner, Art Unit 3781
Read full office action

Prosecution Timeline

May 05, 2025
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734287
FLUID STORAGE CONTAINER
2y 6m to grant Granted Sep 15, 2026
Patent 12721939
AUTOMATIC OPERATIONAL CONTROL BASED ON DETECTED ENVIRONMENTAL STATE
3y 6m to grant Granted Sep 01, 2026
Patent 12721941
NOISE-REDUCING SURGICAL ASPIRATOR
2y 5m to grant Granted Sep 01, 2026
Patent 12708703
FULLY IMPLANTED APHERETER/DIALYZERS FOR INTRACORPOREAL BLOOD PURIFICATION
3y 0m to grant Granted Aug 18, 2026
Patent 12702220
SELF-DISPENSING LOW VOLUME APPLICATOR
3y 10m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+46.3%)
3y 1m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 197 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month